SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Panacea Biotec - Quaterly Results

14 Aug 2024 Evaluate
The Sales for the quarter ended June 2024 of Rs. 568.80 million declined by -36.38% from Rs. 894.10 millions.The Net Loss for the quarter ended June 2024 is Rs. -137.80 millions as compared to Net Profit of Rs. 12.90 millions of corresponding quarter ended June 2023Operating profit Margin for the quarter ended June 2024 slipped to -66.90% as compared to 101.50% of corresponding quarter ended June 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202406 202306 % Var 202406 202306 % Var 202403 202303 % Var
Sales 568.80 894.10 -36.38 568.80 894.10 -36.38 3596.00 2570.70 39.88
Other Income 38.00 33.40 13.77 38.00 33.40 13.77 249.10 344.30 -27.65
PBIDT -66.90 101.50 -165.91 -66.90 101.50 -165.91 390.80 -281.90 -238.63
Interest 32.10 34.60 -7.23 32.10 34.60 -7.23 137.80 100.60 36.98
PBDT -99.00 66.90 -247.98 -99.00 66.90 -247.98 253.00 -382.50 -166.14
Depreciation 50.80 54.00 -5.93 50.80 54.00 -5.93 210.90 245.00 -13.92
PBT -149.80 12.90 -1261.24 -149.80 12.90 -1261.24 42.10 -627.50 -106.71
TAX -12.00 0.00 0.00 -12.00 0.00 0.00 6.60 247.90 -97.34
Deferred Tax -12.00 0.00 0.00 -12.00 0.00 0.00 0.20 247.90 -99.92
PAT -137.80 12.90 -1168.22 -137.80 12.90 -1168.22 35.50 -875.40 -104.06
Equity 61.30 61.30 0.00 61.30 61.30 0.00 61.30 61.30 0.00
PBIDTM(%) -11.76 11.35 -203.61 -11.76 11.35 -203.61 10.87 -10.97 -199.10

Panacea Biotec Share Price

344.90 -13.10 (-3.66%)
20-Apr-2026 14:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1233.50
Cipla 1232.25
Zydus Lifesciences 937.65
Lupin 2327.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×